Krista Nelson received Leadership in Oncology Social Work Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Krista Nelson was awarded the Association of Oncology Social Work’s 2019 Leadership in Oncology Social Work Award.

Nelson serves as secretary of the Association of Community Cancer Centers, program manager of Quality & Research, Cancer Support Services & Compassion, Providence Cancer Institute, Providence Health and Services in Portland, OR.

The award was conferred during the AOSW 35th Annual Conference.

Nelson is a past president of the board of directors of the Association of Oncology Social Work. She is also a past invited director of the American Psychosocial Oncology Society. She serves as an invited director on the board of directors of the National Accreditation Program for Breast Centers and as a director of the American Clinical Social Work Association. In 2015, Nelson was named as a finalist in the Schwartz Center Compassionate Caregiver of the Year Award.

In presenting the award, Leora Lowenthal, AOSW Awards committee member, recognized Nelson for her leadership and strength in fostering partnerships across the wider oncology community.

The Leader in Oncology Social Work Award is sponsored by the American Cancer Society.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login